Kura Oncology (NASDAQ:KURA) saw its stock jump by 9% on Friday. Investors reacted strongly after the company released promising preliminary data from a recent kidney cancer clinical trial.
The trial, known as FIT-001, tested a new drug combination on patients with clear cell renal cell carcinoma (ccRCC). Specifically, researchers evaluated how darlifarnib works alongside cabozantinib. The results highlight significant progress for patients who previously received cabozantinib treatments.
Overall, the data paints an encouraging picture. The combination therapy achieved a 44% objective response rate and an impressive 94% disease control rate. Furthermore, doctors observed tumor shrinkage in 75% of the treated patients.
Looking closer at the study, the analysis focused on a subset of 16 ccRCC patients. All participants had previously undergone immunotherapy and cabozantinib treatments. Their time on the new therapy ranged from 8 to 56 weeks. At the time researchers gathered the data, six patients still remained on the treatment. Notably, even heavily pretreated patients responded well to the new combination. This success included individuals whose disease had simply stabilized during their prior cabozantinib use.
Kura Oncology presented these findings on April 17, 2026, at the International Kidney Cancer Symposium: Europe in Paris. During the presentation, the company confirmed that the drug combination maintains a manageable safety profile across multiple dose levels.
Moving forward, the FIT-001 study continues to evaluate specific dosing schedules. Patients receive darlifarnib at 3 mg, 5 mg, or 8 mg doses, alternating seven days on and off. They take this alongside once-daily cabozantinib doses of either 40 mg or 60 mg. Thanks to these positive early results, the study has officially advanced into Phase 1b dose expansion.
For more investor relations information on Kura Oncology please visit www.ir.kuraoncology.com.
The post Kura Oncology Shares Surge Following Positive Kidney Cancer Trial Data appeared first on PRISM MarketView.